We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

CTI Completes Acquisition of Pacritinib a Highly Selective JAK2 Inhibitor

CTI Completes Acquisition of Pacritinib a Highly Selective JAK2 Inhibitor

CTI Completes Acquisition of Pacritinib a Highly Selective JAK2 Inhibitor

CTI Completes Acquisition of Pacritinib a Highly Selective JAK2 Inhibitor

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "CTI Completes Acquisition of Pacritinib a Highly Selective JAK2 Inhibitor"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cell Therapeutics, Inc. has announced that it has completed its acquisition gaining world-wide rights to S*BIO Pte Ltd.'s ("S*BIO") pacritinib.

Pacritinib is a highly selective oral JAK2 (Janus Associated Kinase 2) inhibitor that demonstrated encouraging clinical activity in phase 1 and 2 clinical studies of patients with primary myelofibrosis ("MF") and MF secondary to other myeloproliferative neoplasms ("MPN").

Pacritinib has orphan drug designation in the United States and Europe for myelofibrosis.

"We believe pacritinib addresses an unmet medical need even in the post-ruxolitinib approval era for the treatment of patients with MF who have low platelet counts based on the lack of treatment emergent thrombocytopenia with pacritinib observed in phase 2 clinical trials," said James A. Bianco, M.D., Chief Executive Officer at CTI.

Bianco continued, "With the encouraging interest we have received from both the medical and investment community, we are re-prioritizing our development programs to accelerate initiation of pacritinib phase 3 clinical studies."

"We are pleased to see continuing development of drugs for the MPN patient community. The acquisition of pacritinib by CTI is proof that a robust pursuit of new treatments is ongoing for MF and related MPN's," said Robert Rosen, Chairman of the MPN Research Foundation.

"S*BIO continues to believe in the potential of this novel drug candidate and looks forward to the future progress of pacritinib development," commented Ms. Tamar Howson, S*BIO's CEO.

S*BIO is a privately held biotechnology company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer.

Under the terms of the asset purchase agreement between CTI and S*BIO, CTI made an upfront payment of $2 million in cash at signing.

At closing, CTI made a final payment of $13 million in cash, along with 15,000 unregistered shares of preferred stock convertible into common stock of CTI.

The asset purchase agreement also includes regulatory success- and sales-based milestone payments, as well as single digit royalties on net sales. CTI will be solely responsible for development and commercialization activities of pacritinib worldwide.